Ignite Creation Date:
2025-12-25 @ 12:21 AM
Ignite Modification Date:
2026-02-20 @ 1:24 AM
Study NCT ID:
NCT03742258
Status:
COMPLETED
Last Update Posted:
2025-06-18
First Post:
2018-11-12
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma
Sponsor:
Northwestern University
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Diffuse Large B-Cell Lymphoma | View |
| None | Diffuse Large B-Cell Lymphoma Activated B-Cell Type | View |
| None | Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | View |
| None | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | View |
| None | High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 … | View |
| None | High Grade B-Cell Lymphoma, Not Otherwise Specified | View |
| None | T-Cell/Histiocyte-Rich Large B-Cell Lymphoma | View |
Keywords: